Symbols

HUMA

Humacyte·NASDAQ

--(--)

HUMA Profile

Humacyte, Inc.

A clinical-stage biotech platform company that develops universally implantable bioengineered human tissues, complex tissue systems, and organs

Industry

Biological Technology

Established Date

07/01/2020

Listing Date

12/01/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

184

Fiscal Year Ends

12-31

Website

www.humacyte.com

Security Type

Common stock

Office address

2525 East North Carolina Highway 54 Durham NC 27713

Business

Introduction

Humacyte, Inc., was incorporated in Delaware on July 1, 2020. The company is a commercialization stage biotechnology platform company dedicated to the development of universally implantable bioengineered human tissue on a commercial scale. Its main product, Symvess, is a cell-free tissue-engineered blood vessel approved by the US Food and Drug Administration for vascular catheters in the event of limb artery injury. The company is also developing a similar product line for other vascular and non-vascular applications.